Nosis Bio
24 employees on LinkedIn · 4 known investors
Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
Founders & leadership
SM
Seth MyersinCo-Founder & CTO
Investors · 4
Competitors · 4
by search overlap
bio12 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Syneos Health9 shared keywordsSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Syndeio Biosciences8 shared keywordsSyndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Nosis Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Nosis Bio do?
- Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
- Who founded Nosis Bio?
- Nosis Bio was founded by Seth Myers.
- Who are Nosis Bio's investors?
- Nosis Bio's investors include AlleyCorp, Madrona Venture Group, Alley Robotics Ventures, KdT Ventures.